Search Result

Results for "

brain regions

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adenosine Receptor (1) Amylin Receptor (2) Apoptosis (1) ASK1 (1) Autophagy (1) Biochemical Assay Reagents (1) COX (1) Cytochrome P450 (1) Dopamine Receptor (2) Dopamine Transporter (1) Dopamine β-hydroxylase (2) Drug Derivative (1) Epigenetic Reader Domain (2) ERK (2) FAAH (2) GCGR (2) GSK-3 (3) Histone Demethylase (1) iGluR (2) Insulin Receptor (2) Interleukin Related (1) mGluR (1) nAChR (2) Opioid Receptor (1) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (2) Serotonin Transporter (1) Src (1) Tau Protein (2) TRP Channel (1) α-synuclein (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Metabolic Disease (3) Neurological Disease (25)

By Targets:

5-HT Receptor (5)

Adenosine Receptor (1)

Amylin Receptor (2)

Apoptosis (1)

ASK1 (1)

Autophagy (1)

Biochemical Assay Reagents (1)

COX (1)

Cytochrome P450 (1)

Dopamine Receptor (2)

Dopamine Transporter (1)

Dopamine β-hydroxylase (2)

Drug Derivative (1)

Epigenetic Reader Domain (2)

ERK (2)

FAAH (2)

GCGR (2)

GSK-3 (3)

Histone Demethylase (1)

iGluR (2)

Insulin Receptor (2)

Interleukin Related (1)

mGluR (1)

nAChR (2)

Opioid Receptor (1)

Phosphodiesterase (PDE) (1)

Prostaglandin Receptor (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reference Standards (2)

Serotonin Transporter (1)

Src (1)

Tau Protein (2)

TRP Channel (1)

α-synuclein (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (1)

Metabolic Disease (3)

Neurological Disease (25)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W115718

Cuprizone 3 Publications Verification	Dopamine β-hydroxylase	Neurological Disease
Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) .

HY-P11274A

Zenagamtide sodium Amycretin sodium; NN 9487 sodium	Amylin Receptor Insulin Receptor GCGR	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .

HY-107531

A 1070722	GSK-3	Neurological Disease Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

HY-P11274

Zenagamtide Amycretin; NN 9487	Amylin Receptor GCGR Insulin Receptor	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-19740

BIA 10-2474 2 Publications Verification	FAAH Autophagy	Neurological Disease
BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC₅₀ values of 50 to 70mg/kg in various rat brain regions.

HY-175748

MK-7337	Radionuclide-Drug Conjugates (RDCs) α-synuclein	Neurological Disease
MK-7337 is an α-synuclein ligand with an affinity of < 1 nM. MK-7337 labeled with ¹¹C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination .

HY-106584

Mosapramine Clospipramine	Drug Derivative Dopamine Receptor 5-HT Receptor	Neurological Disease
Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .

HY-W004425

DMPX 3,7-Dimethyl-1-propargylxanthine	Adenosine Receptor	Neurological Disease
DMPX (3,7-Dimethyl-1-propargylxanthine) is a selective A_2A adenosine receptor (A_2A AR) antagonist that crosses the blood-brain barrier, with a K_i of 11 μM for rat A₂ adenosine receptor and a K_i of 45 μM for rat A₁ adenosine receptor. By blocking A2A receptors in specific brain regions, DMPX protects dopaminergic and GABAergic neurons from mitochondrial dysfunction. DMPX is applicable to research related to depression, Parkinson's disease and Huntington's disease .

HY-124001

N-Docosanoyl taurine	TRP Channel	Neurological Disease
N-Docosanoyl taurine is a lipoamino acid. N-Docosanoyl taurine is a discriminatory metabolity that drive the classification of brain regions .

HY-138693

ST4070	FAAH	Neurological Disease
ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .

HY-W115718R

Cuprizone (Standard)	Reference Standards Dopamine β-hydroxylase	Neurological Disease
Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) .

HY-135507

NAS-181	5-HT Receptor	Neurological Disease
NAS-181 is a potent and selective rat 5-hydroxytryptamine1B (r5-HT1B) antagonist with an K_i value of 47 nM. NAS-181 increases the 5-HTP accumulation in rat brain regions .

HY-163667

Atoxifent	Opioid Receptor	Neurological Disease
Atoxifent is a potent μ-opioid receptor agonist (EC₅₀=0.39 nM). These receptors are found in brain regions that control pain, emotions, habitual learning, and cognition. Atoxifent exhibits strong analgesic effects and a lower risk of respiratory depression. Atoxifent can be used for research in opioid pharmacology and signal transduction .

HY-174923

AZ12943203	Biochemical Assay Reagents GSK-3	Neurological Disease
AZ12943203 (Compound 13e) is a GSK-3 PET radioligand with a K_d of 2.94  nM. AZ12943203 has a significant inhibitory potency toward GSK-3β (IC₅₀: 4.44 nM), and can specifically bind to GSK-3-rich regions of the rodent brain. AZ12943203 can be used for neurodegenerative diseases imaging, particularly Alzheimer’s disease .

HY-59201A

A-582941 dihydrochloride	ERK 5-HT Receptor Epigenetic Reader Domain nAChR	Neurological Disease Metabolic Disease
A-582941 dihydrochloride is a selective, orally active, blood-brain barrier-permeable α7 nAChR agonist, with K_i values of 10.8 nM and 17 nM in rat brain and human frontal cortex, respectively. A-582941 dihydrochloride exhibits agonistic activity at 5-HT3 receptors, with a K_i of 150 nM. A-582941 dihydrochloride triggers phosphorylation of ERK1/2 and CREB, inhibits GSK-3β via Ser-9 phosphorylation, increases acetylcholine release, induces the expression of Arc and c-Fos, activates brain regions associated with working memory and attention, and reduces cell death caused by nerve growth factor (NGF) deprivation. A-582941 dihydrochloride is applicable for the research of Alzheimer's disease and schizophrenia .

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells .

HY-121789

Proadifen	Cytochrome P450	Others
Proadifen is a compound that inhibits cytochrome P450 activity, which can change the excitability of catecholamine-secreting neurons in the brain and have different effects on neurons in different brain regions.

HY-157998

mG2N001	mGluR Src	Others
mG2N001 is a negative allosteric modulator (NAM) (IC₅₀: 93 nM) of the metabotropic glutamate receptor mGluR2 and binds to mGluR2 as an antagonist (Ki: 63 nM). mG2N001 is microparticle- and plasma-stable, and its radioisotope ^[11C]mG2N001 can be used in PET imaging. ^[11C]mG2N001 has good brain heterogeneity and brain penetration, and can selectively accumulate in mGluR2-rich regions, producing high-contrast brain images .

HY-164083

GR65630	5-HT Receptor	Neurological Disease
GR65630 is a potent and selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist. GR65630 can be used to study the expression patterns of 5-HT3 receptors in different brain regions and their possible functions in the central nervous system. GR65630 and its radiolabeled form [ ³H]GR65630 can be used to study the distribution, density and affinity of the receptors .

HY-180422

(-)-UH 232	Dopamine Receptor	Neurological Disease
(-)-UH 232 is a central dopamine (DA) receptor agonist. (-)-UH 232 weakly decreases 3, 4-dihydroxyphenylalanine (DOPA) formation in striatal and limbic brain regions in rats. (-)-UH 232 can be used for the research of neurological diseases including parkinson's disease and schizophrenia .

HY-107531R

A 1070722 (Standard)	Reference Standards GSK-3	Neurological Disease Cancer
A 1070722 (Standard) is the analytical standard of A 1070722 (HY-107531). This product is intended for research and analytical applications. A 1070722 is a potent and selective glycogen synthase K_inase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

HY-182247

D-473	Serotonin Transporter Dopamine Transporter	Neurological Disease
D-473 is an orally active, blood-brain barrier penetrant and serotonin-preferring reuptake inhibitor. D-473 inhibits serotonin, dopamine and norepinephrine transporters, and significantly elevates the extracellular levels of these three neurotransmitters in rat brain regions. D-473 exhibits definite antidepressant-like activity without inducing motor activation. D-473 is widely used in studies related to major depressive disorder .

HY-P990995A

Etalanetug (Mouse IgG2a) 7G6 Antibody; 7G6-IgG2a	Tau Protein	Neurological Disease
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .

HY-59201

A-582941	nAChR 5-HT Receptor ERK Epigenetic Reader Domain	Neurological Disease
A-582941 is a selective, orally active, blood-brain barrier-permeable α7 nAChR agonist, with K_i values of 10.8 nM and 17 nM in rat brain and human frontal cortex, respectively. A-582941 exhibits agonistic activity at 5-HT3 receptors, with a K_i of 150 nM. A-582941 triggers phosphorylation of ERK1/2 and CREB, inhibits GSK-3β via Ser-9 phosphorylation, increases acetylcholine release, induces the expression of Arc and c-Fos, activates brain regions associated with working memory and attention, and reduces cell death caused by nerve growth factor (NGF) deprivation. A-582941 is applicable for the research of Alzheimer's disease and schizophrenia .

HY-183149

BPN-37440	Prostaglandin Receptor Interleukin Related COX	Neurological Disease
BPN-37440 is a blood-brain barrier-permeable, selective, and orally active EP2 receptor inhibitor with an IC₅₀ of 53-60 nM. BPN-37440 inhibits the expression of inflammatory mediators IL-1β and COX-2, with an IC₅₀ of 21 nM for IL-1β and 42 nM for COX-2. BPN-37440 reduces microgliosis in key brain regions of mice with pilocarpine (HY-B0726A)-induced status epilepticus and reverses their working memory and recognition memory deficits. BPN-37440 can be used for research on status epilepticus .

HY-180526

PDE2A-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE2A-IN-2 is a selective and brain-penetrant PDE2A inhibitor (K_i = 5.49 nM and 100 > fold selectivity over other PDE isoforms). The ¹¹C-labeled PDE2A-IN-2 serves as a positron emission tomography (PET) tracer for brain imaging in patients with neurodegenerative diseases. PDE2A-IN-2 educes the radiotracer signal in PDE2A-rich regions in vitro. PDE2A-IN-2 exhibits low binding affinity in vivo. PDE2A-IN-2 can be used for neurodegenerative diseases .

HY-183766

HYF038	ASK1	Neurological Disease
HYF038 is a blood-brain barrier-penetrant ligand of apoptosis signal-regulating kinase 1 (ASK1). When labeled with ¹¹C, HYF038 can be used for ASK1 neuroimaging studies .

HY-116244

Ro 48-8587	iGluR	Cardiovascular Disease Neurological Disease
Ro 48-8587 is a selective AMPA receptor antagonist with an IC₅₀ of 8 nM. Ro 48-8587 functionally inhibits AMPA receptor activity, blocks AMPA-induced depolarization of rat cortical wedges. Ro 48-8587 can be used for the research of ischaemia and seizures .

HY-120681

CGP39653	iGluR	Neurological Disease
CGP39653 is a competitive NMDA receptor antagonist that inhibits receptor function by competing with glutamate for the binding site .

Cat. No.	Product Name	Target	Research Area